A Phase 1 Study of CBX-250 in People With Leukemia

Full Title

CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants with Relapsed or Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Purpose

Researchers want to find the best dose of CBX-250 to treat leukemia that came back or keeps growing after treatment. The people in this study have one of these diseases:

• Acute myeloid leukemia (AML)
• High-risk myelodysplastic syndrome (HR-MDS)
• Chronic myelomonocytic leukemia (CMML)

CBX-250 is a bispecific antibody designed to bind to two different proteins. It attaches to one protein on the surface of cancer cells and to another on immune cells called T cells. CBX-250 may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. It is given as a subcutaneous (under the skin) injection.

Who Can Join

To join this study, there are a few conditions. You must:

• Have AML, HR-MDS, or CMML that came back or keeps growing despite treatment.
• Have recovered from the serious side effects of prior therapies before getting the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.